224 related articles for article (PubMed ID: 26344075)
1. Eosinophil-derived neurotoxin, elastase, and cytokine profile in effusion from eosinophilic otitis media.
Uchimizu H; Matsuwaki Y; Kato M; Otori N; Kojima H
Allergol Int; 2015 Sep; 64 Suppl():S18-23. PubMed ID: 26344075
[TBL] [Abstract][Full Text] [Related]
2. Eosinophil chemoattractants in the middle ear of patients with eosinophilic otitis media.
Iino Y; Kakizaki K; Katano H; Saigusa H; Kanegasaki S
Clin Exp Allergy; 2005 Oct; 35(10):1370-6. PubMed ID: 16238798
[TBL] [Abstract][Full Text] [Related]
3. Antigen-specific IgE in middle ear effusion of patients with eosinophilic otitis media.
Kanazawa H; Yoshida N; Shinnabe A; Iino Y
Ann Allergy Asthma Immunol; 2014 Jul; 113(1):88-92. PubMed ID: 24863399
[TBL] [Abstract][Full Text] [Related]
4. Eosinophilic inflammation in the middle ear induces deterioration of bone-conduction hearing level in patients with eosinophilic otitis media.
Iino Y; Usubuchi H; Kodama K; Kanazawa H; Takizawa K; Kanazawa T; Ohta Y
Otol Neurotol; 2010 Jan; 31(1):100-4. PubMed ID: 19816234
[TBL] [Abstract][Full Text] [Related]
5. Effect of omalizumab on biomarkers in middle ear effusion in patients with eosinophilic otitis media.
Iino Y; Hara M; Hasegawa M; Matsuzawa S; Shinnabe A; Kanazawa H; Yoshida N
Acta Otolaryngol; 2014 Apr; 134(4):366-72. PubMed ID: 24628335
[TBL] [Abstract][Full Text] [Related]
6. Expressions of Eotaxin-3, Interleukin-5, and Eosinophil-Derived Neurotoxin in Chronic Subdural Hematoma Fluids.
Kawaguchi R; Osuka K; Aoyama M; Miyachi S; Takayasu M
J Neurotrauma; 2018 Oct; 35(19):2242-2249. PubMed ID: 29764285
[TBL] [Abstract][Full Text] [Related]
7. IgG4 Expression in Patients with Eosinophilic Otitis Media.
Takahashi M; Oka A; Kariya S; Gion Y; Sato Y; Iwasaki S; Oyamada S; Matsubara A; Okano M
ORL J Otorhinolaryngol Relat Spec; 2021; 83(3):167-171. PubMed ID: 33691317
[TBL] [Abstract][Full Text] [Related]
8. New Insights into Eosinophilic Otitis Media.
Kanazawa H; Yoshida N; Iino Y
Curr Allergy Asthma Rep; 2015 Dec; 15(12):76. PubMed ID: 26546407
[TBL] [Abstract][Full Text] [Related]
9. Eosinophilic otitis media: a new middle ear disease entity.
Iino Y
Curr Allergy Asthma Rep; 2008 Nov; 8(6):525-30. PubMed ID: 18940145
[TBL] [Abstract][Full Text] [Related]
10. Risk factors associated with severity of eosinophilic otitis media.
Kanazawa H; Yoshida N; Yamamoto H; Hara M; Hasegawa M; Matsuzawa S; Shinnabe A; Iino Y
Auris Nasus Larynx; 2014 Dec; 41(6):513-7. PubMed ID: 25199747
[TBL] [Abstract][Full Text] [Related]
11. Role of IgE in eosinophilic otitis media.
Iino Y
Allergol Int; 2010 Sep; 59(3):233-238. PubMed ID: 20657163
[TBL] [Abstract][Full Text] [Related]
12. Eosinophil-derived neurotoxin enhances airway remodeling in eosinophilic chronic rhinosinusitis and correlates with disease severity.
Tsuda T; Maeda Y; Nishide M; Koyama S; Hayama Y; Nojima S; Takamatsu H; Okuzaki D; Kinehara Y; Kato Y; Nakatani T; Obata S; Akazawa H; Shikina T; Takeda K; Hayama M; Inohara H; Kumanogoh A
Int Immunol; 2019 Feb; 31(1):33-40. PubMed ID: 30239772
[TBL] [Abstract][Full Text] [Related]
13. Eosinophilic Otitis Media: the Aftermath of Eosinophil Extracellular Trap Cell Death.
Ueki S; Ohta N; Takeda M; Konno Y; Hirokawa M
Curr Allergy Asthma Rep; 2017 May; 17(5):33. PubMed ID: 28455742
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic criteria of eosinophilic otitis media, a newly recognized middle ear disease.
Iino Y; Tomioka-Matsutani S; Matsubara A; Nakagawa T; Nonaka M
Auris Nasus Larynx; 2011 Aug; 38(4):456-61. PubMed ID: 21251776
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of anti-IL-5 monoclonal antibody mepolizumab in the treatment of eosinophilic otitis media.
Iino Y; Takahashi E; Ida S; Kikuchi S
Auris Nasus Larynx; 2019 Apr; 46(2):196-203. PubMed ID: 30122651
[TBL] [Abstract][Full Text] [Related]
16. [Superoxide dismutase and cytokines in otitis media with effusion].
Dong W; Li Z; Zhou S
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2001 Oct; 15(10):452-4. PubMed ID: 12541690
[TBL] [Abstract][Full Text] [Related]
17. Potential of blood eosinophils, eosinophil-derived neurotoxin, and eotaxin-3 as biomarkers of eosinophilic esophagitis.
Konikoff MR; Blanchard C; Kirby C; Buckmeier BK; Cohen MB; Heubi JE; Putnam PE; Rothenberg ME
Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1328-36. PubMed ID: 17059896
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of anti-IgE therapy for eosinophilic otitis media.
Iino Y; Hara M; Hasegawa M; Matsuzawa S; Shinnabe A; Kanazawa H; Yoshida N
Otol Neurotol; 2012 Sep; 33(7):1218-24. PubMed ID: 22825324
[TBL] [Abstract][Full Text] [Related]
19. Extracellular deposition of eosinophil and neutrophil granule proteins in the IgE-mediated cutaneous late phase reaction.
Leiferman KM; Fujisawa T; Gray BH; Gleich GJ
Lab Invest; 1990 May; 62(5):579-89. PubMed ID: 2188046
[TBL] [Abstract][Full Text] [Related]
20. CD28 and secretory immunoglobulin A-dependent activation of eosinophils: inhibition of mediator release by the anti-allergic drug, suplatast tosilate.
Woerly G; Decot V; Loiseau S; Loyens M; Chihara J; Ono N; Capron M
Clin Exp Allergy; 2004 Sep; 34(9):1379-87. PubMed ID: 15347370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
